Human tumor antigens: Implications for cancer vaccine development

Journal of Molecular Medicine

Volumn 77, Issue 9, 1999, Pages 640-655

  Wang, Rong Fu ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Epitopes; Immunotherapy; Major histocompatibility complex; Melanoma; T cell recognition

Indexed keywords

CANCER VACCINE; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; DENDRITIC CELL; EXPRESSION VECTOR; HELPER CELL; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX RESTRICTION; REVIEW; VACCINE PRODUCTION;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MOLECULAR SEQUENCE DATA; NEOPLASMS; PEPTIDE FRAGMENTS;

EID: 0032736018     PISSN: 09462716     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001099900042     Document Type: Review

References (170)

1. 1. Rosenberg SA, Spiess P, Lafreniere R (1986) A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233:1318-1321
2. 2. Kast WM, Offringa R, Peters PJ, Voordouw AC, Meloen RH, Van der Eb AJ, Melief CJM (1989) Eradication of adenovirus E1-induced tumors by E1 A specific cytotoxic T lymphocytes. Cell 59:603-614
3. 3. Greenberg PD (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281-355
4. 4. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. Preliminary report. N Engl J Med 319:1676-1680
5. 5. Rosenberg SA (1992) The immunotherapy and gene therapy of cancer. J Clin Oncol 10:180-199
6. 6. Greenberg PD, Cheever MA, Fefer A (1981) Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2-lymphocytes. J Exp Med 154:952-963
7. 7. Schild HJ, Kyewski B, Von Hoegen P, Schirrmacher V (1987) CD4+ helper T cells are required for resistance to a highly metastatic murine tumor. Eur J Immunol 17:1863-1866
8. 8. Romerdahl CA, Kripke ML (1988) Role of helper T-lymphocytes in rejection of UV-induced murine skin cancers. Cancer Res 48:2325-2328
9. 9. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357-2368
10. 10. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693-702
11. 11. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Jan RN, Einhorn RN, White DE (1998) Immunologic and therapeutic evaluation of a synthetic tumor-associated peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327
12. 12. Rosenberg SA, Zhai Y, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Seipp CA, Einhorn JH, Roberts B, White DE (1998) Immunizing patients with metastatic melanoma using recombinant adenoviruses encoding MART-1 or gp100 melanoma antigens. J Natl Cancer Inst 90:1894-1900
13. 13. Van Den Eynde B, Lethë B, Van Pel A, De Plaen E, Boon T (1991) The gene coding for a major tumor rejection antigen of tumor P815 is identical to the normal gene of syngeneic DBA/2 mice. J Exp Med 173:1373-1384
14. 14. Brichard V, Van Pel A, Wölfel T, Wölfel C, De Plaen E, Lethë B, Coulie P, Boon T (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178:489-495
15. 15. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, Mattei S, De Plaen ED, Lurquin C, Szikora J-P, Reauld J-C, Boon T (1994) A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 180:35-42
16. 16. Wang R-F, Robbins PF, Kawakami Y, Kang XQ, Rosenberg SA (1995) Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med 181:799-804
17. 17. Wang R-F, Wang X, Johnston SL, Zeng G, Robbins PF, Rosenberg SA (1998) Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens. Cancer Res 58:3519-3525
18. 18. Cox AL, Skipper J, Cehn Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264:716-719
19. 19. Blake J, Johnston JV, Hellstrom KE, Marqardt H, Chen L (1996) Use of combinatorial peptide libraries to construct functional mimics of tumor epitopes recognized by MHC class I-restricted cytolytic T lymphocytes. J Exp Med 184:121-130
20. 20. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W (1995) Immunity to oncogenic proteins. Immunol Rev 145:33-59
21. 21. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109-2117
22. 22. Sahin U, Tureci O, Pfreundschuh M (1997) Serological identification of human tumor antigens. Curr Opin Immunol 9:709-716
23. 23. Old LJ, Chen YT (1998) New paths in human cancer serology. J Exp Med 187:1163-1167
24. 24. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M (1995) Human neoplasms elicit multiple immune responses in the aulologous host. Proc Natl Acad Sci USA 92:11810-11813
25. 25. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang S, Williamson B, Stockert E, Pfreundschuh M, Old LJ (1997) A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 94:1914-1918
26. 26. Tureci O, Sahin U, Schobert I, Koslowski M, Scmitt H, Schild HJ, Stenner F, Seitz G, Rammensee HG, Pfreundschuh M (1996) The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res 56:4766-4772
27. 27. Tureci O, Sahin U, Zwick C, Koslowski M, Seitz G, Pfreundschuh M (1998) Identification of a meiosis-specific protein as a member of the class of cancer-testis antigens. Proc Natl Acad Sci USA 95:5211-5216
28. 28. Chen YT, Gure AO, Tsang S, Stockert E, Jager E, Knuth A, Old LJ (1998) Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A 95:6919-6923
29. 29. Van der Bruggen P, Traversari C, Chomez P, Lurquin C, DePlaen E, Van Den Eynde B, Knuth A, Boon T (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254:1643-1647
30. 30. Jager E, Chen YT, Drijfhout JW, Karbach J, Ringhoffer M, Jager D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A (1998) Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 187:265-270
31. 31. Wang R-F, Johnston SL, Zeng G, Schwartzentruber DJ, Rosenberg SA (1998) A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol 161:3596-3606
32. 32. Jung S, Schluesener HJ (1991) Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 173:273-276
33. 33. Skipper J, Stauss HJ (1993) Identification of two cytotoxic T lymphocyte-recognized epitopes in the Ras protein. J Exp Med 177:1493-1498
34. 34. Celis E, Tsai V, Crimi C, DeMars R, Wentworth PA, Chesnut RW, Grey HM, Sette A, Serra HM (1994) Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci USA 91:2105-2109
35. 35. Zaks TZ, S. A. Rosenberg (1998) Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide specific cytotoxic T lymphocytes which fail to recognize HER-2/neu+ tumors. Cancer Res 58:4902-4908
36. 36. Valmori D, Gileadi U, Servis C, Dunbar PR, Cerottini JC, Romero P, Cerundolo V, Levy F (1999) Modulation of proteasomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J Exp Med 189:895-906
37. 37. Theobald M, Ruppert T, Kuckelkorn U, Hernandez, J, Haussler A, Ferreira EA, Liewer U, Biggs J, Levine AJ, Huber C, Koszinowski UH, Kloetzel PM, Sherman LA (1998) The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope. J Exp Med 188:1017-1028
38. 38. Rammensee HG, Friede T, Stevanoviic S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41:178-228
39. 39. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA (1995) Targeting p53 as a general tumor antigen. Proc Natl Acad Sci USA 92:11993-11997
40. 40. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA (1997) Tolerance to p53 by A2. 1-restricted cytotoxic T lymphocytes. J Exp Med 185:833-841
41. 41. Bouchard B, Fuller BB, Vijayasaradhi S, Houghton AN (1989) Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA. J Exp Med 169:2029-2042
42. 42. Wolfel T, Van Pel A, Brichard V, Schneider J, Seliger B, Meyer Zum Buschenfelde K-H, Boon T (1994) Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolylic T lymphocytes. Eur J Immunol 24:759-764
43. 43. Visseren MJ, Van Elsas A, van der Voort EI, Ressing ME, Kast WM, Schrier PI, Melief CJ (1995) CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J Immunol 154:3991-3998
44. 44. Robbins PF, El-Gamil M, Kawakami Y, Stevens E, Yannelli J, Rosenberg SA (1994) Recognition of tyrosinase by tumor infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res 54:3124-3126
45. 45. Kang X-Q, Kawakami Y, Sakaguchi K, El-Gamil M, Wang R-F, Yannelli JR, Appella E, Rosenberg SA, Robbins PF (1995) Identification of a tyrosinase epitope recognized by HLA-A24 restricted tumor-infiltrating lymphocytes. J Immunol 155; 1343-1348
46. 46. Brichard VG, Herman J, Van Pel A, Wildmann C, Gaugler B, Wolfel T, Boon T, Lethe B (1996) A tyrosinase nonpeptide presented by HLA-B44 is recognized on a human melanoma by autologous cytolylic T lymphocytes. Eur J Immunol 26:224-230
47. 47. Skipper JC, Hendrickson RC, Gulden PH, Brichard V, Van Pel A, Chen Y, Shabanowitz J, Wolfel T, Slingluff CL, Boon T, Hunt D (1996) An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins. J Exp Med 183:527-534
48. 48. Kawakami Y, Eliyahu S, Delgaldo CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA (1994) Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci USA 91:3515-3519
49. 49. Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JB, Appella E, Rosenberg SA (1994) Identification of the immunodominant peptides of the MART-1 human melanoma antigen reeognized by the majority of HLA-A2 restricted tumor infiltrating lymphocytes. J Exp Med 180: 347-352
50. 50. Sensi M, Traversari C, Radrizzani M, Salvi S, Maccalli C, Mortarini R, Rivoltini L, Farina C, Nicolini G, Wolfel T, Brichard V, Boon T, Bordignon C, Anichini A, Parmiani G (1995) Cytotoxic T lymphocyte clones from different patients display limited T-cell receptors variable gene usage in HLA-A2 restricted recognition of Melan/Mart-1 melanoma antigen. Proc Natl Acad Sci USA 92:5674-5678
51. 51. Valmori D, Fonteneau JF, Lizana CM, Gervois N, Lienard D, Rimoldi D, Jongeneel V, Jotereau F, Cerottini JC, Romero P (1998) Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol 160:1750-1758
52. 52. Schneider J, Brichard V, Boon T, Meyer zum Buschenfelde KH, Wolfel T (1998) Overlapping peptides of melanocyte differentiation antigen Melan-A/MART-1 recognized by autologous cytolytic T lymphocytes in association with HLA-B45.1 and HLA-A2.1. Int J Cancer 75:451-458
53. 53. Loftus DJ, Castelli C, Clay TM, Squareina P, Marincola FM, Nishimura MI, Parmiani G, Appella E, Rivoltini L (1996) Identification of epitope mimics recognized by CTL reactive to the melanoma/melanocyte-derived peptide MART-1 27-35. J Exp Med 184:647-657
54. 54. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154:3961-3968
55. 55. Adema GJ, de Boer AJ, van't Hullenaar R, Denijn M, Ruiter DJ, Vogel AM, Figdor CG (1993) Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA. Am J Pathol 143:1579-1585
56. 56. Bakker ABH, Schreurs MWJ, de Boer AJ, Kawakami Y, Rosenberg SA, Adema GJ, Figdor CG (1994) Melanocyte lineage-specific antigen gp100 is recognized by melanocyte-derived tumor-infiltrating lymphocytes. J Exp Med 179:1005-1009
57. 57. Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Sakaguchi K, Appella F, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91:6458-6462
58. 58. Bakker A, Schreurs M, Tafazzul G, de Boer A, Kawakami Y, Adema G, Figdor C (1995) Identification of a novel peptide derived from the melanocyte-specific gp100 antigen as the dominant epitope recognized by an HLA-A2.1-restricted antimelanoma CTL line. Int J Cancer 62:97-102
59. 59. Kawakami Y, Robbins PF, Wang X, Tupesis JP, Parkhurst MR, Kang X, Sakaguchi K, Appella F, Rosenberg SA (1998) Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1,-A2, and-A3 alleles. J Immunol 161:6985-6992
60. 60. Skipper JCA, Kittlesen DJ, Hendrickson RA, Deacon DD, Harthun NL, Wagner SN, Hunt DF, Engelhard VH, Slingluff CL (1996) Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol 157:5027-5033
61. 61. Mattes MJ, Thomson TM, Old LJ, Lloyd KO (1983) A pigmentation-associated, differentiation antigen of human melanoma defined by a precipitating antibody in human serum. Int J Cancer 32:717-721
62. 62. Thomson TM, Mattes JM, Roux L, Old LJ, Lloyd KO (1985) Pigmentation-associated glycoprotein of human melanoma and melanocytes; definition with a mouse monoclonal antibody. J Invest Dermatol 85:169-174
63. 63. Thomson TM, Real FX, Murakami S, Cordon-Cardo C, Old LJ, Houghton AN (1988) Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. J Invest Dermatol 90:459-466
64. 64. Jimenez-Cervantes C, Solano F, Kobayashi T, Urabe K, Hearing VJ, Lozano JA, Garcia-Borron JC (1994) A new enzymatic function in the melanogenic pathway. J Biol Chem 269:17993-18001
65. 65. Wang R-F, Appella E, Kawakami Y, Kang X, Rosenberg SA (1996) Identification of TRP-2 as a human tumor antigen recognized by cytoloxic T lymphocytes. J Exp Med 184:2207-2216
66. 66. Bloom MB, Perry-Lalley D, Robbins PF, Li Y, El-Gamil M, Rosenberg SA, Yang JC (1997) Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med 185:453-460
67. 67. Zeh HJ, 3rd, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC (1999) High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162:989-994
68. 68. Sidney J, Grey HM, Kubo RT, Sette A (1996) Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today 17:261-266
69. 69. Sidney J, Grey HM, Southwood S, Celis E, Wentworth PA, Guercio MFD, Kubo R, Chesnut RW, Sette A (1996) Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Human Immunology 45:79-93
70. 70. Wang R-F, Johnston S, Southwood S, Sette A, Rosenberg SA (1998) Recognition of an antigenic peptide derived from TRP-2 by cytotoxic T lymphocytes in the context of HLA-A31 and -A33. J Immunol 160:890-897
71. 71. Parkhurst MR, Fitzgerald EB, Southwood S, Sette A, Rosenberg SA, Kawakami Y (1998) Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2). Cancer Res 58:4895-4901
72. 72. Traversari C, Van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T (1992) A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 176:1453-1457
73. 73. Van der Bruggen P, Szikora J-P, Boel P, Wildmann C, Somville M, Sensi M, Boon T (1994) Autologous cytolytic T lymphocytes recognize a MAGE-1 nonapeptide on melanomas expressing Cw1601. Eur J Immunol 24:2134-2140
74. 74. Gaugler B, Van Den Eynde B, Van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T (1994) Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 179:921-930
75. 75. Van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, de Smet C, Traversari C, Townsend A, Boon T (1994) A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 24:3038-3043
76. 76. Herman J, van der Bruggen P, Luescher IF, Mandruzaato S, Romero P, Thonnard J, Fleischhauer K, Boon T, Coulie PG (1996) A peptide encoded by the human MAGE3 gene and presented by HLA-B44 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE3. Immunogeneties 43:377-383
77. 77. Boel P, Wildmann C, Sensi ML, Brasseur R, Renauld JC, Coulie P, Boon T, Van der Bruggen P (1995) BAGE: a new gene encoding an antigen recognized on human melanomas by cytolytic T lymphocytes. Immunity 2:167-175
78. 78. Van Den Eynde B, Peeters O, De Backer O, Gaugler B, Lucas S, Boon T (1995) A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma. J Exp Med 182:689-698
79. 79. Brinkmann U, Vasmatzis G, Lee B, Pastan T (1999) Novel genes in the PAGE and GAGE family of tumor antigens found by homology walking in the dbEST database. Cancer Res 59:1445-1448
80. 80. Brinkmann U, Vasmatzis G, Lee B, Yerushalmi N, Essand M, Pastan I (1998) PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. Proc Natl Acad Sci U S A 95:10757-10762
81. 81. Chen ME, Lin SH, Chung LW, Sikes RA (1998) Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 273:17618-17625
82. 82. De Backer O, Arden KC, Boretti M, Vantomme V, De Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, Chomez P, Van den Eynde B, Boon T, van der Bruggen P (1999) Characterization of the GAGE genes that are expressed in various human cancers and in normal testis. Cancer Res 59:3157-3165
83. 83. Lee L, Wang R-F, Wang X, Mixon A, Johnson BE, Rosenberg SA, Schrump DS (1998) NY-ESO-1 may be a potential target for lung cancer immunotherapy. Cancer J Sci Am 5:20-25
84. 84. Stockert E, Jager E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ (1998) A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 187:1349-1354
85. 85. Gaugler B, Brouwenstijn N, Vantomme V, Szikora JP, Van der Spek CW, Patard JJ, Boon T, Schrier P, Van den Eynde BJ (1996) A new gene coding for an antigen recognized by autologous cytolytic T lymphocytes on a human renal carcinoma. Immunogenctics 44:323-330
86. 86. Van Elsas A, Nijman HW, Van der Minne CE, Mourer JS, Kast WM, Melief CJ, Schrier PI (1995) Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21ras peptide presented by HLA-A*0201. Int J Cancer 61:389-396
87. 87. Houbiers JGA, Nijman HW, van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJH, Brand A, Momburg F, Kast WM, Melief CJ M (1993) In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 23:2072-2077
88. 88. Nijman HW, Houbiers JGA, Vierboom MPM, van der Burg SH, Drijfhout JW, D'Amaro J, Kenemans P, Melief CJM, Kast WM (1993) Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol 23:1215-1219
89. 89. Nijman HW, van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ (1994) p53, a potential target for tumor-directed T cells. Immunol Lett 40:171-178
90. 90. Coulie PG, Lehmann F, Lethe B, Herman J, Lurquin C, Andrawiss M, Boon T (1995) A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc Natl Acad Sci USA 92:7976-7980
91. 91. Wolfel T, Hauer M, Schneider J, Serrano M, Wolfel C, Klehmann-Hieb E, De Plaen E, Hankeln T, Meyer Zum Buschenfelde K-H, Beach D (1995) A p161NK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science 269:1281-1284
92. 92. Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes & Development 9:1149-1163
93. 93. Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA (1996) A mutated β-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med 183:1185-1192
94. 94. Grunwald GB (1993) The structural and functional analysis of cadherin calcium-dependent cell adhesion molecules. Curr Opin Cell Biol 5:797-805
95. 95. Hoschuetzky H, Aberle H, Kemler R (1994) β-catenin mediates the interaction of the cadherin-catenin complex with epidermal growth factor receptor. J Cell Biol 127:1375-1380
96. 96. Becker K-F, Atkinson MJ, Reich U, Becker I, Nekarda H, Siewert JR, Hofler H (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. Cancer Res 54:3845-3852
97. 97. Kawanishi J, Kato J, Sasaki K, Fujii S, Watanabe M, Niitsu Y (1995) Loss of E-cadherin-dependent cell-cell adhesion due to mutation of the β-catenin gene in a human cancer cell line, HSC-39. Mol Cell Biol 15:1175-1181
98. 98. Korinek V, Baker N, Morin PJ, van Wichen D, de Weger R, Kinzler KW, Vogelstein B, Clevers H (1997) Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/-colon carcinoma. Science 275:1784-1787
99. 99. Morin PJ, Sparks AB, Korinek V, Barker N, Clevers H, Vogelstein B, Kinzler KW (1997) Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 275:1787-1790
100. 100. Rubinfeld B, Robbins P, El-Gamil M, Albert I, Porfiri E, Polakis P (1997) Stabilization of beta-catenin by genetic defects in melanoma cell lines. Science 275:1790-1792
101. 101. Mandruzzato S, Brasseur F, Andry G, Boon T, van der Bruggen P (1997) A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med 186:785-793
102. 102. Ioannides CG, Fisk B, Jerome KR, Irimura T, Wharton JT, Finn OJ (1993) Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol 151:3693-3703
103. 103. Magarian-Blander J, Domenech N, Finn OJ (1993) Specific and effective T-cell recognition of cells transfected with a truncated human mucin cDNA. Ann NY Acad Sci 690: 231-243
104. 104. Finn OJ, Jerome KR, Henderson RA, Pecher G, Domenech N, Magarian-Blander B-B. SM (1995) MUC-1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev 145:61-89
105. 105. Apostolopoulos V, Karanikas V, Haurum JS, MeKenzie IF (1997) Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. J Immunol 159:5211-5218
106. 106. Domenech N, Henderson RA, Finn OJ (1995) Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 155:4766-4774
107. 107. Apostolopoulos V, Lofthouse SA, Popovski V, Chelvanayagam G, Sandrin MS, McKenzie IF (1998) Peptide mimics of a tumor antigen induce functional cytotoxic T cells. Nat Biotechnol 16:276-280
108. 108. Ioannides CG, Fisk B, Pollack MS, Frazier ML, Wharton JT, Freedman RS (1993) Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on nonovarian tumour clones. Scand J Immunol 37:413-424
109. 109. Yoshino I, Peoples GE, Geoedegebauure PS, Mazizrz R, Eberlein TJ (1994) Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 152:2393-2400
110. 110. Disis ML, CAlenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA (1994) Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16-20
111. 111. Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cylotoxic T lymphocytes recognize the same HER2/neuderoed peptide. Proc Natl Acad Sci USA 92:432-436
112. 112. Linchan DC, Goedegebuure PS, Peoples GE, Rogers SO, Eberlein TJ (1995) Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer. J Immunol 155:4486-4491
113. 113. Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E (1999) Identification of HLA-A3-restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro immunization with peptide-pulsed dendritic cells. Cancer Res 59:431-435
114. 114. Wang R-F, Parkhurst MR, Kawakami Y, Robbins PF, Rosenberg SA (1996) Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. J Exp Med 183:1131-1140
115. 115. Spiropoulou CF, Nichol ST (1993) A small highly basic protein is encoded in overlapping frame within the P gene of vesicular stomatitis virus. J Virol 67:3103-3110
116. 116. Schwartz S, Felber BK, Pavlakis GN (1992) Mechanism of translation of monocistronic and multicistronic human immunodeficiency virus type 1 mRNAs. Mol Cell Biol 12:207-219
117. 117. Lethe B, Lucas S, Michaux L, De Smet C, Godelaine D, Serrano A, De Plaen E, Boon T (1998) LAGE-1, a new gene with tumor specificity. Int J Cancer 76:903-908
118. 118. Aarnoudse CA, van den Doel PB, Heemskerk B, Schrier PI (1999) Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. Int J Cancer 82:442-448
119. 119. Mayrand SM, Schwarz DA, Green WR (1998) An alternative translational reading frame encodes an immunodominant retroviral CTL determinant expressed by an immunodeficiency-causing retrovirus. J Immunol 160:39-50
120. 120. Mayrand SM, Green WR (1998) Non-traditionally derived CTL epitopes: exceptions that prove the rules? Immunol Today 19:551-556
121. 121. Guilloux Y, Lucas L, Brichard VG, Van Pel A, Viret C, De Plaen E, Brasseur F, Lethe B, Jotereau F, Boon T (1996) A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 183: 1173-1183
122. 122. Robbins P, El-Gamil M, Li YF, Fitzgerald E, Kawakami Y, Rosenberg SA (1997) The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol 159:303-308
123. 123. Lupetti R, Pisarra P, Verrecchia A, Farina C, Nicolini G, Anichini A, Bordignon C, Sensi M, Parmiani G, Traversari C (1998) Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. J Exp Med 188:1005-1016
124. 124. Ostrand-Rosenberg S (1994) Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 6:722-727
125. 125. Pardoll DM, Topalian SL (1998) The role of CD4(+) T cell responses in antitumor immunity. Curr Opin Immunol 10: 588-594
126. 126. Toes RE, Ossendorp F, Offringa R, Melief CJ (1999) CD4 T Cells and their role in antitumor immune responses. J Exp Med 189:753-756
127. 127. Frasca L, Piazza C, Piecolella E (1998) CD4+ T cells orchestrate both amplification and deletion of CD8+ T cells. Crit Rev Immunol 18:569-594
128. 128. Tisch R, McDevitt H (1996) Insulin-dependent diabetes mellitus. Cell 85:291-297
129. 129. O'Garra A, Steinman L, Gijbels K (1997) CD4+ T-cell subsets in autoimmunity. Curr Opin Immunol 9:872-883
130. 130. Bona CA, Casares S, Brumeanu TD (1998) Towards development of T-eell vaccines. Immunol Today 19:126-133
131. 131. Riddell SR, Greenberg PD (1995) Principles for adoptive T cell therapy of human viral diseases. Annu Rev Immunol 13:545-586
132. 132. Kalams SA, Walker BD (1998) The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 188:2199-2204
133. 133. Markus NR, Rosenberg SA, Topalian SL (1995) Analysis of cytokine secretion by melanoma-specific CD4+ T lymphocytes. J Interferon Cytokine Res 15:739-746
134. 134. Dadmarz R, Sgagias MK, Rosenberg SA, Schwartzentruber DJ (1995) CD4+ T lymphocytes infiltrating human breast cancer recognize autologous tumor in an MHC-class II restricted fashion. Cancer Immunol Immunother 40:1-9
135. 135. Takahashi T, Chapman PB, Yang SY, Hara I, Vijayasaradhi S, Houghton AN (1995) Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J Immunol 154:772-779
136. 136. Topalian SL, Rivoltini L, Mancini M, Markus NR, Robbins PF, Kawakami Y, Rosenberg SA (1994) Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci USA 91:9461-9465
137. 137. Topalian SL, Gonzales MI, Parkhurst M, Li YF, Southwood S, Sette A, Rosenberg SA, Robbins PF (1996) Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med 183:1965-1971
138. 138. Kobayashi H, Kokubo T, Sato K, Kimura S, Asano K, Takahashi H, Iizuka H, Miyokawa N, Katagiri M (1998) CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res 58:296-301
139. 139. Halder T, Pawelec G, Kirkin AF, Zeuthen J, Meyer HE, Kun L, Kalbacher H (1997) Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res 57:3238-3244
140. 140. Li K, Adibzadeh M, Halder T, Kalbacher H, Heinzel S, Muller C, Zeuthen J, Pawelec G (1998) Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother 47:32-38
141. 141. Chaux P, Vantomme V, Stroobant V, Thielemans K, Corthals J, Luiten R, Eggermont AM, Boon T, van der Bruggen P (1999) Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4(+) T Lymphocytes. J Exp Med 189:767-778
142. 142. Manici S, Sturniolo T, Imro MA, Hammer J, Sinigaglia F, Noppen C, Spagnoli G, Mazzi B, Bellone M, Dellabona P, Protti MP (1999) Melanoma cells present a MAGF-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189:871-876
143. 143. Pieper R, Christian RF, Gonzales MI, Nishimura MI, Gupta G, Settlage RE, Shabanowitz J, Rosenberg SA, Hunt DF, Topalian SL (1999) Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T Cells. J Exp Med 189:757-766
144. 144. Wang R-F, Wang X, Alwood AC, Topalian SL, Rosenberg SA (1999) Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284: 1351-1354
145. 145. Wang R-F, Wang X, Rosenberg SA (1999) Identification of a novel MHC class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4+ T cells. J Exp Med 189:1659-1667
146. 146. Nordlund JJ, Kirkwood M, Forget BM, Milton G, Albert DM, Lerner AB (1983) Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol 9: 689-695
147. 147. Nanda NK, Sercarz EE (1995) Induction of anti-self-immunity to cure cancer. Cell 82:13-17
148. 148. Bystryn J-C, Rigel D, Friedman RJ, Kopf A (1987) Prognostic significance of hypopigmentation in malignant melanoma. Arch Dermatol 123:1053-1055
149. 149. Richards JM, Mehta N, Ramming K, Skosey P (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10:1338-1343
150. 150. Rosenberg SA, White DE (1996) Vitiligo in patients with melanoma: normal tissue antigens can be targeted for cancer immunotherapy. J Immunother 19:81-84
151. 151. Ogg GS, Rod Dunbar P, Romero P, Chen JL, Cerundolo V (1998) High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 188:1203-1208
152. 152. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP (1998) gp100/pmel 17 is a murine tumor rejection antigen: induction of "Self-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med 188:277-286
153. 153. Hara I, Takechi Y, Houghton AN (1995) Implicating a role for immune recognition of self in tumor rejection: passive immunization against the Brown locus protein. J Exp Med 182:1609-1614
154. 154. Takechi Y, Hara I, Naftzger C, Xu Y, Houghton AN (1996) A melanosomal membrane protein is a cell surface target for melanoma therapy. Clin Cancer Res 2:1837-1842
155. 155. Hirschowitz EA, Leonard S, Song W, Ferris B, Leopold PL, Lewis JJ, Bowne WB, Wang S, Houghton AN, Crystal RG (1998) Adenovirus-mediated expression of melanoma antigen gp75 as immunotherapy for metastatic melanoma. Gene Ther 5:975-983
156. 156. Naftzger C, Takechi Y, Kohda H, Hara T, Vijayasaradhi S, Houghton AN (1996) Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. Proc Natl Acad Sci USA 93:14809-14814
157. 157. Weber LW, Bowne WB, Wolchok JD, Srinivasan R, Qin J, Moroi Y, Clynes R, Song P, Lewis JJ, Houghton AN (1998) Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest 102:1258-1264
158. 158. Overwijk WW, Lee DS, Surman DR, Irvine KR, Touloukian CH, Chan CC, Carroll MW, Moss B, Rosenberg SA, Restifo NP (1999) Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci USA 96:2982-2987
159. 159. Boon T, Van der Bruggen P (1996) Human tumor antigens recognized by T lymphocytes. J Exp Med 183:725-729
160. 160. Marchand M, van Baren N, Weynants P, Brichard V, Dreno B, Tessier MH, Rankin E, Parmiani G, Arienti F, Humblet Y, Bourlond A, Vanwijck R, Lienard D, Beauduin M, Dietrich PY, Russo V, Kerger J, Masucci G, Jager E, De Greve J, Atzpodien J, Brasseur F, Coulie PG, van der Bruggen P, Boon T (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219-230
161. 161. Parkhurst MR, Salgaller M, Southwood S, Robbins P, Sette A, Rosenberg SA, Kawakami Y (1996) Improved induction of melanoma reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A0201 binding residues. J Immunol 157:2539-2548
162. 162. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392:245-252
163. 163. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D (1998) Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 4:328-332
164. 164. Zhong L, Granelli-Piperno A, Choi Y, Steinman RM (1999) Recombinant adenovirus is an efficient and non-perturbing genetic vector for human dendritic cells. Eur J Immunol 29:964-972
165. 165. Ockert D, Schmitz M, Hampl M, Rieber EP (1999) Advances in cancer immunotherapy. Immunol Today 20:63-65
166. 166. Timmerman JM, Levy R (1999) Dendritic cell vaccines for cancer immunotherapy. Annu Rev Med 50:507-529
167. 167. Wan Y, Emtage P, Foley R, Carter R, Gauldie J (1999) Murine dendritic cells transduced with an adenoviral vector expressing a defined tumor antigen can overcome anti-adenovirus neutralising immunity and induce effective tumor regression. Int J Oncol 14:771-7716
168. 168. Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, Roberts BL (1999) Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 163:699-707
169. 169. Liu MA (1998) Vaccine developments. Nat Med 4:515-519
170. 170. Ying H, Zaks TZ, Wang RF, Irvine KR, Kammula US, Marincola FM, Leitner WW, Restifo NP (1999) Cancer therapy using a self-replicating RNA vaccine. Nat Med 5:823-827